Janux Therapeutics (JANX) Other Working Capital Changes (2020 - 2026)

Janux Therapeutics (JANX) has reported Other Working Capital Changes for 7 consecutive years, with $46.3 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Other Working Capital Changes rose 6509.57% year-over-year to $46.3 million; the TTM figure through Mar 2026 stood at $46.4 million (up 884.38% YoY), while the FY2025 annual figure was $827000.0, down 74.79% from the prior year.
• Other Working Capital Changes climbed to $46.3 million in Q1 2026 per JANX's latest filing, from $827000.0 in the prior quarter.
• Across five years, Other Working Capital Changes topped out at $46.3 million in Q1 2026 and bottomed at -$4.6 million in Q3 2023.
• Historically, Other Working Capital Changes has averaged $2.7 million across 5 years, with a median of -$733000.0 in 2024.
• Annual changes were most pronounced in 2022 — Other Working Capital Changes sank 9438.46% — and 2026, when it jumped 6509.57%.
• Janux Therapeutics' Other Working Capital Changes stood at -$1.5 million in 2022, then declined by 27.49% to -$1.9 million in 2023, then surged by 356.56% to $5.0 million in 2024, then plunged by 83.41% to $827000.0 in 2025, then surged by 5494.56% to $46.3 million in 2026.
• Business Quant data shows JANX's Other Working Capital Changes at $46.3 million in Q1 2026, $827000.0 in Q4 2025, and -$1.0 million in Q3 2025.